Search for: "State v. Ferro" Results 21 - 40 of 43
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Oct 2012, 4:10 am by David J. DePaolo
  In California, a recent Workers' Compensation Appeals Board panel opinion imposed the maximum statutory penalty against a carrier for what it said was an unreasonable delay in the approval of psychotropic medications for an injured worker.In Ferro v. [read post]
20 May 2009, 1:16 am
Ferro APPELLATE DIVISIONTHIRD DEPARTMENTGovernment Response to FOIL Request for Papers on Senate Employee Did Not Satisfy Statute, Senate Rule Matter of Polokoff-Zakarin v. [read post]
26 May 2023, 2:45 am by Public Employment Law Press
Selected summaries of decisions alleging unlawful discrimination in violation of state and, or, federal civil rights laws posted by New York Public Personnel Law. [read post]
26 May 2023, 2:45 am by Public Employment Law Press
Selected summaries of decisions alleging unlawful discrimination in violation of state and, or, federal civil rights laws posted by New York Public Personnel Law. [read post]
5 Mar 2009, 6:30 am
This is the third in the four-part series from the brain injury case of Gregory Joseph Gagnon, et al. v. [read post]
7 Aug 2017, 7:42 am
Ferro, Esquire, entered his appearance on May 22, 2014. [read post]
13 Feb 2009, 8:00 am
(IPKat)   United States US General Sen Gregg withdraws from nomination to be next Secretary of Commerce (Inventive Step) (Patently-O) Influx of Big Content lawyers at Department of Justice: cause for concern? [read post]
15 Jul 2014, 9:00 am by Benjamin Wittes
Susana Sanchez Ferro considered the implications for domestic intelligence services of the increasing necessity of global intelligence initiatives. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
  Updated draft guidelines have not been released by the agencies, but the agencies have stated a goal of releasing new guidelines by the end of this year. [read post]